Management

Jeffrey R. Bergen

Chief Executive Officer

Mr. Bergen, an Enlyton founder, formally joined the company in June 2007 as Chief Executive Officer. From 2001-2007 Mr. Bergen served as President and CEO of BioCrystal, Ltd. where he led a technology group that generated 40 patents in three technology areas: improved fluorescence-based assays; high performance cell culture and cancer immunotherapy. The fluorescence business unit was sold to Invitrogen Corporation in 2005 and the cell culture product business to Thermo Fisher Scientific, Inc. in June 2007. Portions of BioCrystal’s cancer IP are under license to Enlyton, Ltd. From 1987-2001 Mr. Bergen was Director of Marketing and Business Development for Lake Shore, Inc., a world leader in products for the physics field and the materials sciences. Before then he was President and a founder of Queue Systems. Queue developed novel cryopreservation storage and automated laboratory-scale fermentation systems. Queue was sold to Rheem Corporation in 1987.

Mr. Bergen holds a BA/BS in Chemistry from Columbia University, and membership in Sachems, Columbia Senior Men’s Honorary.

Mr. Bergen is developing business strategies, assessing market opportunities and driving value creation as Enlyton moves into its next stage of product development, strategic partnering and product commercialization.

Edward W. Martin, Jr. MD, FACS

Chief Science Officer

Dr. Martin is a Professor of Surgery at The Ohio State University (OSU) and an Attending Surgical Oncologist at the Arthur G. James Cancer Hospital. Dr. Martin’s vision of intraoperative assessment of tumor biology and dissemination has spanned nearly 30 years of progress at OSU. Leading a team of innovators beginning in 1979, Dr. Martin developed the first hand-held probe capable of detecting cancer cells of colorectal, pancreatic, gastric, ovarian, prostatic, and breast origin in real-time in the operating room. The use of such hand-held probes has become the standard of care in the surgical management of many malignant and benign disease processes. Dr. Martin has significant patent and commercialization experience. His endeavors have generated six patents, and spawned four start-up companies which have developed an additional 78 U.S. patents.

Dr. Martin holds a degree in Medicine from Meharry Medical College (Nashville, TN) and completed his surgical training at OSU (Columbus, OH). His specialty training includes National Institutes of Health (NIH), OSU, and American Cancer Society Advanced Fellowship.

As Enlyton CSO, Dr. Martin coordinates resources involved in molecular tracer development and associated clinical trials at OSU.

Edward W. Martin III MBA

Chief Operations Officer

Mr. Martin has over a decade experience in nuclear medicine research (Research Associate, BioCrystal Ltd, Westerville Ohio.), biotechnology business management (COO Interthyr Corporation, Athens, OH) and biomedical business consulting (independent contractor). Mr. Martin previously worked in the publishing industry (Graphic de France, Woburn MA) where he was responsible for new product development and product management.

Mr. Martin holds a Masters degree in Business Administration from Northeastern University (Boston, MA).

As Enlyton COO, Martin oversees business operations, facilitates strategic technology development, and coordinates commercialization activities of the company.

Mark W. Arnold MD, FACS

Chief Medical Officer

Dr. Arnold is a Professor of Surgery at The Ohio State University (OSU) and has organized and participated in multiple clinical trials. Dr. Arnold is a colorectal cancer surgeon and a collaborator with Dr. Martin for the past 20 years; an inventor of a radiation-based laparoscopic method for determining cancer treatment modality.

Dr. Arnold holds a degree in Medicine from New York University and completed his general surgery training at Jackson Memorial Hospital, University of Miami Medical Center (Miami, FL) and colorectal fellowship at Grant Medical Center (Columbus, OH).

As Enlyton CMO, Dr. Arnold oversees protocol and documentation development for IND submissions and will coordinate clinical trials.